Bruce L. Levine

The American Chestnut Foundation — United States

Medicine · Health Sciences

102h-index65.8kcitations544works27.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(328), Immunotherapy and Immune Responses(130), Immune Cell Function and Interaction(104), Virus-based gene therapy research(67), Acute Lymphoblastic Leukemia research(63)

Publications543 total

Genomic approaches to accelerate American chestnut restoration
Science·2026· 1 citedOpen Access
Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia
Blood·2025
CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy
Nature Biomedical Engineering·2025· 1 cited
Multiplex engineering using microRNA-mediated gene silencing in CAR T cells
Frontiers in Immunology·2025· 2 citedOpen Access
Engineering Relapse-Resistant CAR T-Cells for Blood Cancers (Penta T-Cells)
Cytotherapy·2025Open Access
Cellular gene therapy access in Africa: a multifactorial feasibility analysis for implementation
Cytotherapy·2025· 2 cited
Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells
The Lancet·2025· 10 cited
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-based interventions
Cytotherapy·2025· 4 citedOpen Access
Improving American chestnut resistance to two invasive pathogens through genome-enabled breeding
2025· 2 citedOpen Access
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Nature Medicine·2025· 58 cited
Perceptions of the impact of character education
2024Open Access
TET2 regulates early and late transitions in exhausted CD8 <sup>+</sup> T cell differentiation and limits CAR T cell function
Science Advances·2024· 18 citedOpen Access
Editor’s Note: Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
Cancer Research·2024· 1 citedOpen Access
Regulatory Considerations for Genome-Edited T-cell Therapies
Cancer Immunology Research·2024· 7 citedOpen Access
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
Journal of Clinical Investigation·2024· 4 citedOpen Access
TET2 regulates early and late transitions in exhausted CD8 <sup>+</sup> T-cell differentiation and limits CAR T-cell function
2024Open Access
Contract development and manufacturing organization selection: critical considerations that can make or break your cell and gene therapy development
Cytotherapy·2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Nature Medicine·2024· 232 cited
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Nature Medicine·2024· 188 citedOpen Access
261 Synergistic antitumor effects of mouse mesothelin-directed CAR (mmeso-CAR) T cells and αCD40 in a syngeneic model of PDAC
Regular and Young Investigator Award Abstracts·2023Open Access
page 1 of 28Next →

Frequent Co-authors

Carl H. June(49), Simon F. Lacey(21), J. Joseph Melenhorst(19), Michael Kalos(12), David L. Porter(11), Stephan A. Grupp(10), Gabriela Plesa(10), Irina Kulikovskaya(9), Joseph A. Fraietta(8), Noelle V. Frey(7), Anne Chew(7), Zhaohui Zheng(7), Marcela V. Maus(7), Wei‐Ting Hwang(7), Regina M. Young(7), Edward A. Stadtmauer(7), Yangbing Zhao(7), Bruce R. Blazar(7), Shannon L. Maude(6), David E Ambrose(6)